DOSAGE INDEX / SINGLE
Semaglutide
Research, reported schedules and supply planning.
Review semaglutide weight-loss trials, cardiovascular and kidney outcomes, withdrawal evidence, current product indications and safety considerations.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- The source describes 0.25 mg weekly initially, with four-week stages through 0.5, 1 and 1.7 mg to a 2.4 mg maintenance example
- Frequency
- Once weekly
- Cycle / observation period
- Four weeks at each initial stage; maintenance is indication-dependent
- Route / research model
- Subcutaneous
Approved injection products are supplied as solutions. The source’s powder-vial calculations do not establish formulation equivalence.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–28 | 0.25 mg | Weekly |
| Days 29–56 | 0.5 mg | Weekly |
| Days 57–84 | 1 mg | Weekly |
| Days 85–112 | 1.7 mg | Weekly |
Compare the product label or clinical-study schedule
Adults meeting Wegovy weight-management eligibility; this summary concerns injection, not tablets or Ozempic.
The Wegovy injection label starts at 0.25 mg weekly for weeks 1–4, then 0.5 mg for weeks 5–8, 1 mg for weeks 9–12 and 1.7 mg for weeks 13–16. Adult weight-management maintenance is 1.7 or 2.4 mg weekly, with 2.4 mg recommended. The June 2026 label permits clinician-selected 7.2 mg after at least four weeks tolerating 2.4 mg when additional weight reduction is indicated. Escalation may be delayed for intolerance.
Prescription assessment is required. Contraindications include personal/family medullary thyroid carcinoma or MEN 2. Read the complete label for gastrointestinal, pancreatic, gallbladder, pregnancy and other risks.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
The approved product is supplied as a prepared solution, with no user reconstitution. Its handling instructions do not establish a diluent for a separately supplied research powder.
Vial comparison
Initial 16 weeks only; maintenance is not included: 13.8 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 5 mg | 3 |
| 10 mg | 2 |
| 15 mg | 1 |
| 20 mg | 1 |
| 30 mg | 1 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- SELECT enrolled 17,604 people with established cardiovascular disease and overweight or obesity, without diabetes. Over a mean 39.8-month follow-up, the cardiovascular composite occurred in 6.5% with semaglutide and 8.0% with placebo. The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90. The composite included cardiovascular death, nonfatal heart attack or nonfatal stroke. Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%. [1]
- FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease. The primary composite included kidney failure, a substantial decline in estimated kidney filtration, or kidney-related or cardiovascular death. There were 331 first events with semaglutide and 410 with placebo, corresponding to a hazard ratio of 0.76, with a 95% confidence interval of 0.66 to 0.88. Median follow-up was 3.4 years; early stopping followed a prespecified interim analysis. [2]
- The STEP 1 extension analyzed 327 participants after medication and structured lifestyle intervention ended at week 68. In the semaglutide group, the earlier mean loss was 17.3%; over the following year, participants regained 11.6 percentage points relative to starting weight, leaving a net 5.6% loss. The extension analyses were exploratory. [3]
- Ozempic's boxed warning concerns rodent thyroid C-cell tumors; human relevance is unknown. Personal or family medullary thyroid carcinoma and MEN2 are contraindications. Its warnings also address pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney injury, diabetic retinopathy complications, hypoglycemia with certain diabetes medicines, and aspiration around anesthesia or deep sedation. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 60 entries mapped from 5 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- SELECT publication
- FLOW original report
- Original extension publication
- Prescribing information
- FDA (2026): Wegovy semaglutide injection and tablets: current prescribing informationRegulatory / product information · Listed in reference bibliography.
- New England Journal of Medicine (2021): Once-weekly semaglutide in adults with overweight or obesity: STEP 1Further reading · Listed in reference bibliography.
- ClinicalTrials.gov: STEP 1 study record NCT03548935Trial registry · Listed in reference bibliography.
- The Lancet (2021): Semaglutide 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes: STEP 2Further reading · Listed in reference bibliography.
- JAMA (2021): Continued weekly subcutaneous semaglutide and weight-loss maintenance: STEP 4Further reading · Listed in reference bibliography.
- New England Journal of Medicine (2016): Semaglutide and cardiovascular outcomes in patients with type 2 diabetes: SUSTAIN-6Further reading · Listed in reference bibliography.
- The Lancet (2025): Once-weekly semaglutide 7.2 mg in adults with obesity: STEP UPFurther reading · Listed in reference bibliography.
- Journal of Medicinal Chemistry (2015): Discovery of the once-weekly glucagon-like peptide-1 analogue semaglutideFurther reading · Listed in reference bibliography.
- ClinicalTrials.gov: STEP 4 study record NCT03548987Trial registry · Listed in reference bibliography.
- CDC: Preventing unsafe injection practices and handling multidose vialsGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf: Best practices for injections and related proceduresFurther reading · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.